Get 20% lifetime commission for referring investors to digrin.com
here.
Inhibikase Therapeutics, Inc. (IKT) Financials
IKT Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 163.6 million | 10.3 million |
| March 31, 2026 | 173.3 million | 5.7 million |
| Dec. 31, 2025 | 181.2 million | 8.3 million |
| Sept. 30, 2025 | 79.6 million | 6.7 million |
IKT Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -12.4 million | 5.3 million |
| March 31, 2026 | -12.1 million | 5.6 million |
| Dec. 31, 2025 | -8.0 million | 4.5 million |
| Sept. 30, 2025 | -10.6 million | 4.5 million |
IKT Net Income
No data available :(
IKT Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 159.0 million | - | - |
| March 31, 2026 | 170.4 million | - | - |
| Dec. 31, 2025 | 178.8 million | - | - |
| Sept. 30, 2025 | 77.3 million | - | - |
IKT Shares Outstanding
IKT Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | - | 13.4 million | 7.7 million | - |
| March 31, 2026 | - | 10.8 million | 7.4 million | - |
| Dec. 31, 2025 | 452023 | 6.4 million | 6.8 million | - |
| Sept. 30, 2025 | 452023 | 7.6 million | 5.6 million | - |
IKT Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | - | - |
| March 31, 2026 | - | - |
| Dec. 31, 2025 | - | 36811 |
| Sept. 30, 2025 | - | 23688 |
IKT
Price: $2.36
52 week price:
Earnings Per Share: -0.44 USD
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 146895
Market Capitalization: 336.3 million